Autoimmune disease.
D000293:Adolescent; D000974:Antibodies, Antinuclear; D000937:Antigen-Antibody Reactions; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000145:classification / Q000150:complications / Q000175:diagnosis / Q000209:etiology / Q000235:genetics / Q000473:pathology; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D003165:Complement System Proteins / Q000032:analysis; D003345:Corticosterone / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D006968:Hypersensitivity, Delayed; D006969:Hypersensitivity, Immediate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008221:Lymphoid Tissue / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D003165:Complement System Proteins; D001379:Azathioprine; D003345:Corticosterone; D008727:Methotrexate